Navigation Links
Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net
Date:4/18/2008

NEW YORK, April 18 /PRNewswire-FirstCall/ -- Rik J. Deitsch, Chairman and Chief Executive Officer of Nutra Pharma Corporation (OTC Bulletin Board: NPHC) (http://www.NutraPharma.com) will be updating the investment community through his personal profile on MyWallst.net available at http://www.wallst.net. The dynamic profile will include exclusive interviews with Rik J. Deitsch, company blogs on which investors can comment, his personal stock watchlist, photos of company products and links to recent press.

Visit Rik J. Deitsch's profile on My.wallst.net at http://my.wallst.net/profile.php?ID=20002.

Stay updated about Nutra Pharma Corporation, ask Rik a question or post a comment on his personal page. Join Nutra Pharma's message board to discuss company activity with other interested parties, "invest" in OTCBB: NPHC through the Rookie Challenge and join his financial social network today.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://my.wallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of compliance solutions to publicly traded companies. We have received ten thousand dollars from Nutra Pharma Corporation for media and advertising services. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site.

About Nutra Pharma:

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ('MS'). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Contact: Nutra Pharma Corporation

877-895-5647

IR@NutraPharma.com


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
2. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
3. NutraCea Appoints New Chief Financial Officer
4. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
7. Nutraceutical Reports Fiscal 2008 Q1 Results
8. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
9. NutraCea Files Universal Shelf Registration Statement
10. NutraCea Provides Update on Domestic Operations
11. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: